Sotorasib Shows Intracranial Activity in Patients with Mutated Adenocarcinoma of the Lung and Untreated Active Brain Metastases.

Publication

Sotorasib Shows Intracranial Activity in Patients with Mutated Adenocarcinoma of the Lung and Untreated Active Brain Metastases.

Journal Paper/Review - Aug 26, 2022

Koster Kira-Lee, Appenzeller Christina, Lauber Arno, Früh Martin, Schmid Sabine

Citation

Koster K, Appenzeller C, Lauber A, Früh M, Schmid S. Sotorasib Shows Intracranial Activity in Patients with Mutated Adenocarcinoma of the Lung and Untreated Active Brain Metastases. Case Rep Oncol 2022; 15:720-725.

Type

Journal Paper/Review (English)

Journal

Case Rep Oncol 2022; 15

Publication Date

Aug 26, 2022

Issn Print

1662-6575

Pages

720-725

Brief description/objective

Treatment with sotorasib has shown intracranial complete responses and continued intracranial stabilization in mutated non-small-cell lung carcinoma (NSCLC) patients with previously treated, stable brain metastases in a post hoc analysis of the ongoing CodeBreaK 100 trial. We present the case of a patient with mutant adenocarcinoma of the lung with active untreated brain metastases with a nearly complete intracranial response only 6 weeks after start of sotorasib illustrating the benefit of sotorasib in patients with active, previously untreated brain metastases in mutated NSCLC.